Harmony Biosciences Holdings (HRMY) Short term Debt (2021 - 2026)
Harmony Biosciences Holdings (HRMY) posted Short term Debt of $20.0 million for Q1 2026, little changed sequentially from $20.0 million in Q4 2025, and up 14.29% YoY from $17.5 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Short term Debt (2021 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Short term Debt for 6 years, with the latest figure at $20.0 million in Q1 2026.
- Quarterly Short term Debt rose 14.29% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (up 14.29% YoY) and the FY2025 annual result came in at $20.0 million, up 23.08% from the prior year.
- Short term Debt held at $20.0 million in Q1 2026 per HRMY's latest filing, from $20.0 million in the prior quarter.
- Over five years, Short term Debt peaked at $20.0 million in Q3 2025 and troughed at $2.0 million in Q1 2022.
- A 5-year average of $12.5 million and a median of $15.0 million in 2023 frame the typical range for Short term Debt.
- The sharpest annual moves came in 2022 and 2023: Short term Debt changed 0.0% in 2022, then soared 650.0% in 2023.
- Over 5 years, Short term Debt stood at $2.0 million in 2022, then jumped by 650.0% to $15.0 million in 2023, then climbed by 8.33% to $16.2 million in 2024, then advanced by 23.08% to $20.0 million in 2025, then changed by 0.0% to $20.0 million in 2026.
- According to Business Quant data, Short term Debt over the past three periods registered $20.0 million, $20.0 million, and $20.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.00 Mn |
| Mar 31, 2026 | 20.00 Mn |
| Dec 31, 2025 | 20.00 Mn |
| Sep 30, 2025 | 20.00 Mn |
| Jun 30, 2025 | 18.75 Mn |
| Mar 31, 2025 | 17.50 Mn |
| Dec 31, 2024 | 16.25 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Mar 31, 2024 | 15.00 Mn |
| Dec 31, 2023 | 15.00 Mn |
| Sep 30, 2023 | 15.00 Mn |
| Jun 30, 2023 | 11.00 Mn |
| Mar 31, 2023 | 6.50 Mn |
| Dec 31, 2022 | 2.00 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 2.00 Mn |
| Dec 31, 2021 | 2.00 Mn |
| Sep 30, 2021 | 2.00 Mn |